Timberlyne Therapeutics
PrivateLast Round
Series A
Jan 9, 2025
Est. Valuation
$242.6M
Total Funding Raised
$180M
Company Overview
Timberlyne Therapeutics is a biotechnology company that develops and commercializes monoclonal antibody therapies for autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Timberlyne Therapeutics Comparables
Compare Timberlyne Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biogen | 81% | |
| Hangzhou Shangjian Biotechnology Co., Ltd. | 79% | |
| CASI Pharmaceuticals | 78% |
Timberlyne Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 9, 2025 |
Key People
Founding team and executive leadership
Timberlyne Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series A |
| Boyu Capital | Series A |
| Mountainfield Venture Partners | Series A |
| Braidwell | Series A |
| 3H Health Investment | Series A |
| Abingworth | Series A |
| Lilly Asia Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 9, 2025
$180M round raised
Timberlyne Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Timberlyne Therapeutics's valuation, stock price, and market status.
Is Timberlyne Therapeutics a public or private company?
Timberlyne Therapeutics is a private company.
What is the current stock price of Timberlyne Therapeutics?
Timberlyne Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Timberlyne Therapeutics worth (valuation)?
Valuation information for Timberlyne Therapeutics is not publicly available.
Can I buy Timberlyne Therapeutics stock?
Timberlyne Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Timberlyne Therapeutics's last funding round?
Timberlyne Therapeutics's most recent funding round was Series A on January 9, 2025.
Who are the main investors in Timberlyne Therapeutics?
Key investors in Timberlyne Therapeutics include Bain Capital Life Sciences, Abingworth, Venrock.
Will Timberlyne Therapeutics IPO soon?
No public IPO plans have been announced for Timberlyne Therapeutics.
How can I track Timberlyne Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Timberlyne Therapeutics's secondary market activity and sign up for updates.